Apollon, a membrane-associated inhibitor of apoptosis protein, protects cells against apoptosis and is upregulated in certain tumor cells. In this study, the effects of Apollon protein knockdown by RNA interference on the growth of human HeLa, HT-1080 and MCF-7 cells in vitro and in vivo were investigated. An oncolytic adenovirus (ZD55) containing the RNA polymerase III-dependent U6 promoter to express short hairpin RNA (shRNA) directed against Apollon (ZD55-siApollon) was constructed. Our data show that ZD55-siApollon successfully exerts a gene knockdown effect and causes the inhibition of tumor cell growth both in culture and in athymic mice in vivo. Cell cycle analysis, 4 0 ,6-diamidino-2-phenylindole staining and western blot analysis reveal that ZD55-siApollon-mediated suppression of Apollon induces apoptosis. Intratumoral injection of ZD55-siApollon significantly inhibits tumor growth in HT-1080 xenograft mice. Furthermore, ZD55-siApollon enhances the antitumor effect of 5-fluorouracil, a chemotherapeutic agent. In conclusion, these results suggest that the depletion of Apollon by oncolytic adenovirus-shRNA delivery system provides a promising method for cancer therapy.
Introduction
The inhibitor of apoptosis proteins (IAPs) have been implicated in the regulation of apoptosis. [1] [2] [3] [4] [5] A hallmark of IAPs is the presence of one to three baculovirus IAP repeat (BIR) domains, through which the IAPs bind and thereby inhibit caspases. [6] [7] [8] Certain IAPs (such as mammalian proteins XIAP, CIAP1, CIAP2 and ML-IAP) also possess a C-terminal RING finger, which can act as E3 ubiquitinligases and might enable IAPs to ubiquitylate proteins that interact with them directly and target them for degradation by the proteasome. 9 In recent years, it was apparent that IAPs belong to a large group of so-called BIR-domain-containing proteins, BIRPs. 10 In addition to the IAPs mentioned above, proteins of the BIRP branch typically contain single BIR domains and seem to be important for cell division. The prototypical member of them is the mammalian protein survivin, which contains a single BIR domain and lacks the RINGfinger motif. 3, 11 Bruce (BIR-containing ubiquitin-conjugating enzyme) was first identified in the mouse 12 and is a giant membrane-associated IAP protein (528 kDa), which bears a single survivin-like BIR domain at its N-terminal region and an ubiquitin-conjugating domain close to its C terminus. Bruce is highly conserved and its homologs have been identified in human (Apollon) and Drosophila (dBruce). 13, 14 Complete inactivation of the Bruce gene in mice results in perinatal lethality and growth deficiencies. 15 In Drosophila, overexpression of dBruce can inhibit cell death induced by the proapoptotic Smac analogs Reaper and Grim.
14 Several lines of evidence show that the Apollon can protect cells against apoptosis and functions as an IAP by binding the active caspases via its single BIR domain. [16] [17] [18] Furthermore, studies also show that Apollon can promote ubiquitination of the IAP antagonist Smac, which depends on the integrity of both the catalytically active ubiquitin-conjugating domain and the correctly folded BIR domain. [16] [17] [18] Apollon is upregulated in some drug-resistant cancer cells, and antisense oligonucleotides against Apollon significantly sensitizes tumor cells to apoptosis induced by chemotherapy agents. 13 These findings suggest that Apollon has an antiapoptotic role and has been considered to be an attractive target with respect to molecular therapy of cancer.
RNA interference (RNAi) is a conserved biological process by which double-stranded RNA (dsRNA) inhibits gene expression in a sequence-dependent manner via the degradation of corresponding mRNA. This process is initiated by an event by which dsRNA is cleaved into 21-to 23-nucleotide short interfering RNAs (siRNAs) by Dicer, a member of the RNase III family. These siRNAs mediate the suppression of the complementary mRNA through a phylogenetically conserved cellular pathway. 19 In mammalian cells, the application of RNAi holds the possibility of cancer gene therapy. However, chemically synthesized siRNA is expensive, has low transfection efficiency and can lead only a transient knockdown of the target gene. To surmount these limitations, several groups have developed DNA-vector-mediated or virus-vectormediated mechanisms to express short hairpin RNAs (shRNAs) that can be converted into siRNAs in vivo. [20] [21] [22] [23] Oncolytic adenoviral vector permits the efficient delivery and stable expression of shRNA constructs in a range of mammalian cells. Furthermore, oncolytic adenoviral vector has the distinct advantage of propagation in tumor cells, which can infect adjacent tumor cells and leave normal cells almost unaffected. 24 In this study, we designed an oncolytic adenovirus encoding shRNA against Apollon and investigated its efficacy in regard to suppression of Apollon expression in cancer cells and consequent antitumor potential in vitro and in vivo.
Results

Inhibition of Apollon expression by plasmid encoding an Apollon shRNA
Three plasmid vectors encoding U6 promoter-driven shRNAs against different target sites within the Apollon transcript, pBS/U6-siApollon-1, pBS/U6-siApollon-2 and pBS/U6-siApollon-3 (Figures 1a and b) , were constructed. To verify the effective target site in the Apollon coding region, three different plasmid vectors targeting Apollon were transfected into 293T cells. Reduction of Apollon mRNA and protein expression was monitored by real-time quantitative reverse transcription-PCR (RT-PCR) and western blot, respectively. As shown in Figures 1c and d , pBS/U6-siApollon-2 significantly caused more decrease of mRNA and protein level of Apollon than the other two plasmid vectors. Thus, the shRNA synthesized by pBS/U6-siApollon-2 was used in the adenovirus-mediated silencing system.
Oncolytic adenovirus-mediated shRNA suppresses Apollon expression in tumor cells
In consideration of efficient delivery of shRNA to tumor cells, we designed an oncolytic adenovirus encoding Apollon RNA interference as cancer therapy L Chu et al shRNA that targets the Apollon transcript (ZD55-siApollon-2). The vector is shown in Figure 2 . The backbone of it was an E1B-55 kDa-gene-deleted serotype 5 adenovirus. As silencing construct, we chose the shRNA expression cassette from pBS/U6-siApollon-2, consisting of the RNA polymerase III U6 promoter and a hairpin RNA with a stem of 21 nucleotides targeting the Apollon gene.
HeLa, HT-1080 and MCF-7 cells were infected with ZD55-siApollon-2 or ZD55-siGFP as control. Real-time quantitative RT-PCR analysis showed a decrease in Apollon mRNA levels 48 h after being infected with ZD55-siApollon-2 in all three cell lines. After 96 h, the amount of Apollon mRNA remaining in cells was 11.5% for HeLa, 5.0% for HT-1080 and 8.9% for MCF-7, respectively. It was statistically significantly lower than that in cells infected with ZD55-siGFP (Po0.05, respectively, Figure 3a) .
Western blot was performed to determine whether the reduced levels of Apollon mRNA observed after ZD55-siApollon-2 infection also reflected reduced Apollon protein expression (Figures 3b and c) . The suppression of Apollon expression was detected as early as 24 h after infection and the gene knockdown effect was maintained after 96 h. Densitometric analysis revealed that 96 h after infection with ZD55-siApollon-2, the suppression of Apollon protein was up to 97.9% in HeLa cells, 98.5% in HT-1080 cells and 80.5% in MCF-7 cells, respectively. The control vector ZD55-siGFP had no effect on Apollon expression level. These results indicated that shRNA Apollon RNA interference as cancer therapy L Chu et al respectively). As the second proliferation parameter, colony-forming assay was conducted to test whether targeting of Apollon could reduce the ability of tumor cells to form colonies. Twenty-four hours after infection, we seeded cells onto six-well culture plates and evaluated colony formation after 12 days. Cells infected with ZD55-siApollon-2 formed smaller colonies less than mock-infected cells or cells infected with ZD55-siGFP ( Figure 4b) .
Next, the tumorigenic capability of HT-1080 cells in vivo was investigated. HT-1080 cells were infected as above and inoculated (5 Â 10 6 cells per animal) subcutaneously into nude mice. The resultant tumor volumes were monitored. The mock-infected cells gave rise to tumors within 2 weeks in all mice (n ¼ 6) and reached a size beyond 1000 mm 3 within 5 weeks ( Figure  4c ). All the mice in the ZD55-siGFP group also developed large tumors beyond 1000 mm 3 within 9 weeks. In contrast, none of the mice in the ZD55-siApollon-2 group developed tumors at the 10th week. Although the mice in the ZD55-siApollon-2 group had a small tumor size (means±s.d.) of 43.5±12.5 mm 3 at the second week, these tumors disappeared within the following 3 weeks. Similar results were observed in HeLa cells (data not shown).
To confirm the specificity of RNAi effects, we determined whether cell growth could be restored by exogenous Apollon expressed in ZD55-siApollon-2-treated cells. The assay was performed by first transfecting HeLa, HT-1080 and MCF-7 cells with one of the following constructs: no DNA (mock transfection), pcDNA3-myc and pcDNA3-myc-Apollon. After a 2 h recovery from the transfection, cells were infected with ZD55-siApollon-2. MTT assay revealed a cell viability decrease in mock-or pcDNA3-myc-rescued cells. In contrast, the expression of exogenous Apollon in cells blocked ZD55-siApollon-2-induced grow inhibition with an 80.9-85.2% cell viability at day 5 ( Figure 4d ). Taken together, these data indicated that ZD55-mediated shRNA targeting Apollon exhibited a specific inhibitory effect on the cell growth of tumor cells.
ZD55 expressing shRNA against Apollon induces apoptosis in tumor cells
To investigate whether ZD55-siApollon-2 has the apoptosis-inducing potential in tumor cells, flow cytometric analysis was performed 24 h after infection of adenovirus into three tumor cell lines. Cell death was represented by the fraction of cells in sub-G1 phase. In all cell lines tested, infection with ZD55-siApollon-2 increased the percentage of cells in sub-G1 phase ( Figure  5a ). A total of 22.07% of HeLa and 23.15% of MCF-7 cells underwent apoptosis after being ZD55-siApollon-2 infected versus 13.08 and 13.91% after being ZD55-siGFP infected, respectively. Higher apoptotic index was found in HT-1080 cells after infection with ZD55-siApollon-2 (27.35%). We also confirmed the apoptosis of three cell lines by 4 0 ,6-diamidino-2-phenylindole (DAPI) staining after treatment with adenovirus for 48 h. Nuclear fragmentation and chromatin clumping were shown in the tumor cells infected with ZD55-siApollon-2, whereas no apoptotic changes were detected in mock-infected cells or cells infected with ZD55-siGFP (Figure 5b ).
The components of the apoptosis signaling cascade in Apollon-depleted tumor cells were investigated by immunoblotting. HT-1080 cells were mock infected or infected with adenovirus at an MOI of 1. Whole cell lysates were collected at different time and analyzed using the appropriate antibodies against caspase-8, caspase-3 and poly ADP-ribose polymerase. As shown in Figure 5c , the cleavage products p20 of caspase-8, p17 of caspase-3 and p85 from poly ADP-ribose polymerase could be detected 24 h after the treatment of ZD55-siApollon-2. The cleavage became dramatically evident after 72 h. Infection with ZD55-siGFP did not affect the status of these components until 72 h after the infection. Similar results were also observed in HeLa and MCF-7 cells (data not shown).
To demonstrate whether exogenous Apollon expression could suppress ZD55-siApollon-2-induced apoptosis. HeLa, HT-1080 and MCF-7 cells were first transfected with pcDNA3-myc, pcDNA3-myc-Apollon or no DNA as mock, and then infected with ZD55-siApollon-2, and 24 h later the cells were analyzed for apoptosis. Flow cytometric analysis showed a substantial inhibition of apoptosis in pcDNA3-myc-Apollon-transfected cells (Figure 5d ). Taken together, these results not only proved the specificity of RNAi inhibition, but also demonstrated that ZD55 expressing shRNA against Apollon induced caspase-dependent apoptosis in tumor cells.
Intratumoral injection of ZD55 delivering shRNA against Apollon suppresses tumor growth in vivo
The antitumor activity of ZD55-siApollon-2 was assessed in nude mice xenografts. A total of 5 Â 10 6 HT-1080 cells were inoculated subcutaneously into nude mice. When the tumor size reached 100-150 mm 3 , seven mice in each group received the intratumoral injection of ZD55-siGFP or ZD55-siApollon-2, each at totally 2 Â 10 9 plaqueforming unit (PFU) per tumor, or phosphate-buffered saline (PBS) as a control. All the mice in the PBS group and the ZD55-siGFP group developed large tumors. At week 7, four mice in the PBS group and two mice in the ZD55-siGFP group developed tumors beyond 1000 mm 3 . In contrast, the tumor growth was obviously inhibited in the ZD55-siApollon-2 group and the tumor size was significantly smaller compared with that observed in the PBS group (Po0.05) (Figure 6a ).
Tumor specimens were obtained from tumor-bearing animals 3 weeks after treatment, and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling analysis showed that predominant apoptosis was observed in the ZD55-siApollon-2-treated tumors and the apoptotic index was 11-fold higher than that of PBS group (Po0.05) and threefold higher than that of ZD55-siGFP group (Figures 6b and c) . Immunohistochemistry was used to evaluate the effect of ZD55-siApollon-2 on Apollon expression in vivo. As shown in Figure 6d , the Apollon level of tumors treated with ZD55-siApollon-2 was markedly lower than those treated with PBS or ZD55-siGFP. Thus, ZD55-siApollon-2 exerted the antitumor effect in vivo associated with inhibition of Apollon expression and tumor cell apoptosis.
ZD55-siApollon-2 enhances the antitumor effect of 5-FU in vitro and in vivo
For the possibility of clinical application, it is interesting to know whether an additive effect could be achieved by combining ZD55-siApollon-2 with a chemotherapeutic ), ZD55-siGFP (1 MOI), ZD55-siApollon-2 (1 MOI) or the combination of the two, and MTT assay was performed at a 24 h interval. As shown in Figure 7a , 5 days after treatment with 5-FU, the cell viability was decreased to 36.9, 35.4 and 46.9% in three tumor cell lines, respectively. The cytotoxic effect of ZD55-siApollon-2 appeared distinct in HeLa cells (with 30.1% cell viability) and weaker in HT-1080 and MCF-7 cells (with 40.1 and 41.1% cell viability, respectively). Most importantly, the cell viability was remarkably decreased to 3.2, 15.4 and 18.5% at day 5 when both 5-FU and ZD55-siApollon-2 were applied under the same conditions, while no significant antitumor effects of 5-FU and ZD55-siGFP combinations were observed.
Finally, we investigated the combined effect of ZD55-siApollon-2 and 5-FU on the growth of pre-established tumors. HT-1080 xenografts were established in nude mice as mentioned above. When tumors reached about 120 mm 3 , we administered 5-FU, ZD55-siGFP, ZD55-siApollon-2 or viruses followed by 5-FU. 5-FU minimally delayed tumor growth; however, the combination of ZD55-siApollon-2 and 5-FU almost completely arrested tumor growth relative to PBS-treated controls (Po0.05, Figure 7b ). Most importantly, five out of seven combined-treated mice experienced a complete eradication of established tumors, whereas none of animals in other groups performed complete tumor repression. These data suggested that the combination of ZD55-siApollon-2 and 5-FU provided a potent antitumor effect.
Discussion
As Apollon inhibits apoptosis similar to other IAP proteins and is upregulated in certain tumors, its protein has been considered to be a promising molecular target for cancer therapy. It has been demonstrated that Apollon ubiquitinates and facilitates proteasomal degra- Apollon RNA interference as cancer therapy L Chu et al dation of Smac and caspase-9. Qiu et al. 25 reported that Nrdp1-mediated downregulation of BRUCE promotes apoptosis. Recently, Ren et al. 26 indicated that BRUCE acts at a step upstream of mitochondria and the mutation of BRUCE leads to upregulation of the tumor suppressor p53, which activates Pidd/caspase-2 and Bax/Bak, leading to mitochondrial apoptosis. However, the therapeutic potential of downregulation of Apollon has not yet been assessed. In this study, we reported that suppression of Apollon by oncolytic adenovirusmediated shRNA achieved significant therapeutic efficacy.
For the application of RNAi technology in cancer therapy, it is important to choose an efficient delivery system for transduction of siRNA into target cells. Three plasmid vectors were constructed, which encode shRNAs against different target sites within the Apollon transcript. The most effective one was founded by realtime quantitative RT-PCR and western blot (Figures 1c  and d) . Although our data showed that the plasmid vector-mediated shRNAs for Apollon inhibits its expression, this method has several limitations, such as low transfection efficiency and nonspecificity in vivo expression, and thereby is not sufficient to be widely used in cancer therapy. So, an oncolytic adenovirus (ZD55) was designed to express shRNA. ZD55 is an E1B 55 kDa genedeleted adenovirus harboring a wild-type E3 region. The functions of E1B 55 kDa include p53 degradation, RNA export and host protein shutoff, and the loss of these functions is an important determinant of the tumor cell selectivity of the ZD55 virus. 27 Compared with nonreplicating adenoviral vectors, ZD55 selectively replicates in tumor cells and thereby augments the spread of therapeutic gene expression. We previously have reported that ZD55-delivering therapeutic genes (for example TRAIL and IL-24) suppresses tumor growth and induces tumor cell apoptosis. 28, 29 We speculate that the potency of ZD55 could be similarly improved by the expression of synthetic lethal shRNAs against endogenous antiapoptotic genes instead of expressing proapoptotic transgenes.
Here, ZD55 was used to transfer shRNAs driven by polymerase III U6 promoter and a significant suppression of endogenous Apollon expression was achieved in HeLa, MCF-7 and HT-1080 cells (Figure 3 ). Our study indicated that the loss of Apollon increased the apoptotic cells to 22.07-27.35% (Figure 5a ) with a transfection efficiency above 80% (data not shown). The decreasing endogenous Apollon led to a clear increase in the levels of active caspase-8 and caspase-3 ( Figure 5c ). These findings indicated that Apollon is essential to prevent apoptosis and the knockdown of Apollon triggered a caspase-dependent apoptotic process. Meantime, it was observed that the downregulation of Apollon had an antiproliferation effect on the tumor cells in culture and suppressed HT-1080 tumorigenicity (Figure 4) . It is reasonable to speculate that the observed reduction in the growth capability of tumor cells resulted from the induction of apoptosis. Expression of exogenous Apollon restored tumor cell growth (Figure 4d ) and suppressed These results confirmed the specificity of RNAi. Furthermore, our in vivo data showed a significant tumor regression due to dramatic induction of tumor cell apoptosis ( Figure 6 ). On the other hand, ZD55-siGFP had a considerable tumor growth-inhibitory effect relative to the mock group (Figures 4c and 6a) . It indicated that oncolytic adenovirus could by itself cause cancer cell lyse and this effect would enhance the antitumor effect. In addition, ZD55-siApollon-2 improved the antitumor effect of 5-FU in cell cultures, and the coadministration resulted in a complete elimination of tumor xenografts (Figure 7) . Although the underlying mechanism for this contribution of the RNAi agent to 5-FU is not clear, the observations suggest a potent combinatorial therapy approach for cancer. Although RNAi is more potent than other gene silencing methods, 30, 31 there are some quantitative limitations inherent in RNAi technology. Specifically, RNAi knocks down gene expression, but generally does not eliminate it. For therapeutic purpose, partial downregulation of a pathogenic gene is necessary but not sufficient. Many studies have described notable success in slowing the rate of tumor progression and prolonging the experimental animals' survival by siRNA treatments, but still very few tumors were eradicated, a necessary step before applying this technology in human trials. [32] [33] [34] In the present study, ZD55-siApollon-2 silencing of Apollon gene in vivo has been shown to slow the rate of tumor progression, but the tumors were not eliminated. In contrast, complete tumor eradication in five out of seven xenograft mice was observed when tumors were coinjected with ZD55-siApollon-2 and 5-FU (Figure 7b) . Hence, the combined treatment of RNAi and chemotherapy may provide a promising method for cure therapy of cancer.
Materials and methods
Cell culture and transfection HEK293 cell line (human embryonic kidney containing the E1A region of Ad5) was obtained from Microbix Biosystems (Ontario, Canada). Cells were maintained in Dulbecco's modified Eagle's medium (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal bovine serum (GIBCO BRL), 4 mM glutamine, 50 U ml À1 penicillin and 50 mg ml À1 streptomycin at 37 1C in a humidified air atmosphere with 5% CO 2 . 293T cells, human cervical cancer cell line HeLa, human fibrosarcoma cell line HT-1080 and human breast cancer cell line MCF-7 were obtained from the American Type Culture Collection (Rockville, MD, USA) and were maintained under conditions recommended by this organization. For transient transfection of plasmids, cells Apollon RNA interference as cancer therapy L Chu et al were transfected using a Lipofectamine reagent following the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA).
Plasmid vectors
Plasmids were constructed by use of the pBS/U6 parental vector. 35 Three siRNA sequences from various coding regions of human Apollon gene were selected (Figure 1b) . To generate an intermediate plasmid for cloning shRNAs targeted to Apollon, the oligonucleotide 5 0 -GGCCAGTATGGCTTGCTAGTA-3 0 annealed with the oligonucleotide 5 0 -AGCTTACTAGCAAGCCA TACTGGCC-3 0 was inserted into the ApaI (blunted) and HindIII sites of pBS/U6. The inverted motif, containing a 6-nucleotide spacer and a polymerase III termination signal of five thymidine residues (5 0 -AGCTTACTAG CAAGCCATACTGGCCCTTTTTG-3 0 , 5 0 -AATTCAAAA AGGGCCAGTATGGCTTGCTAGTA-3 0 ), was subcloned into the HindIII and EcoRI sites of the intermediate plasmid to generate pBS/U6-siApollon-1. The same protocol was used to generate pBS/U6-siApollon-2, pBS/U6-siApollon-3 and pBS/U6-siGFP (a control shRNA in which the sequence targeted against green fluorescent protein gene). Expression plasmid pcDNA3-myc-Apollon containing the full-length Apollon cDNA was kindly provided by Mikihiko Naito (Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan). Four silent nucleotide changes were introduced in the region complementary to siRNA. The region AATGTTGACG was mutated to CATGCTAACA, leaving the amino-acid sequence unchanged. Mutations were introduced using QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol.
Adenoviral vectors
The Ad5-derived oncolytic vector ZD55 carrying a 55 kDa gene deletion in E1B and containing the wildtype E3 region has been described previously. 36 The BamHI fragment of pBS/U6-siApollon-2 containing an inverted repeat sequence with 21 bases homologous to the Apollon gene downstream of the U6 promoter was subcloned into the BglII sites of the plasmid pZD55 to generate pZD55-siApollon-2. Oncolytic adenovirus expressing shRNA was generated by homologous recombination in HEK293 cells between pZD55-siApollon-2 and adenovirus packaging plasmid pBHGE3 (Microbix Biosystems). The same protocol was used to generate ZD55-siGFP. Large-scale preparations of ZD55-siApollon-2 and ZD55-siGFP were performed by ultracentrifugation on cesium chloride. The shRNA expression cassettes were examined by PCR on the final products, and functional PFU titers were determined by limitingdilution plaque titration on HEK293 cells.
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen). Oligo(dT) 18 -primed, first-strand cDNA was synthesized from total RNA (1 mg per 20 ml reaction) using the RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, Vilnius, Lithuania). Real-time PCR was performed using a DNA Engine Opticon2 machine (MJ Research, Waltham, MA, USA). PCR was carried out with 5 ml of 10Â PCR buffer, 2 mM MgCl 2 , 0.8 mM deoxynucleotide triphosphate, 0.5 mM of each primer, 1.25 U of Taq DNA polymerase (MBI Fermentas), 2 ml of 20 Â SYBR Green I dye (Invitrogen) and 1 ml of sample cDNA solution in a total volume of 50 ml. The thermal cycling conditions were an initial 5-min denaturation step at 94 1C and 40 cycles of 94 1C for 30 s, 59 1C for 30 s and 72 1C for 30 s. PCRs for GAPDH were performed as the inner control. Results of the real-time PCR were processed according to the method described. 37 The mRNA levels of adenovirusinfected cells were standardized against the mock cells. Primers used for the quantification of Apollon and GAPDH mRNA were as follows: Apollon, sense, 5 0 -AATGTGCTTCCAACCCTTCCTTTC-3 0 , and antisense, 5
0 -TGTGGCTCAGTTTGATTCACGCTA-3 0 ; GAPDH, sense, 5 0 -TCCATGACAACTTTGGTATC-3 0 , and antisense, 5
0 -TTCAGCTCAGGGATGACCTT-3 0 .
MTT assay
Cells were seeded at 6000 cells per well in flat-bottomed 96-well plates. The next day, cells were treated with 1 MOI of ZD55-siApollon-2, ZD55-siGFP or untreated (mock) for 1, 2, 3, 4 or 5 days. At the end of culture, 10 ml of MTT (5 mg ml
À1
) was added to each well and plates were placed at 37 1C for 4 h. The medium was then removed and 100 ml of 0.04 M HCl-isopropanol solution was added to each well to lyse the cells. Absorbance was measured at 570 nm using a Microplate Reader (Bio-Rad, Tokyo, Japan). Four replicate wells were tested per assay, and each experiment was repeated three times.
Colony-forming assay
Twenty-four hours after adenovirus infection, cells were seeded onto six-well culture plates at a concentration of 10 3 cells per well and were cultured for 12 days. Following removal of the medium, the wells were rinsed twice with PBS stained with crystal violet solution (2% crystal violet in 20% methanol) for 15 min at room temperature. Colonies were counted and the number of colonies formed in the mock-infected cultures was set as the value of 100% colony formation.
Flow cytometric analysis
To quantitate apoptosis by flow cytometry, both adherent and floating cells were harvested 24 h after adenovirus infection, washed with PBS and fixed in 70% ethanol at 4 1C overnight. Fixed samples were washed again with PBS, treated with RNase A (100 mg ml 
DAPI staining
Cells were cultured in coverlips and treated with adenoviral vectors for 2 days or untreated (mock). Cells were fixed with 4% paraformaldehyde and stained with DAPI (Sigma) at 1 mg ml À1 for 10 min. Fluorescence was visualized with an Olympus standard fluorescence microscope (Olympus, Tokyo, Japan).
Western blot analysis
Total proteins were detected by western blot with horseradish peroxidase-conjugated secondary antibodies using standard procedures. Antibodies were purchased from BD Biosciences (San Jose, CA, USA) (Apollon), Cell 
Animal experiments
Animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals. Five-week-old female athymic nude mice were purchased from Shanghai Experimental Animal Center (Shanghai, China). For analysis of the tumorigenic capacity of HT-1080 cells in vivo, cells were either mock infected or infected with ZD55-siGFP or ZD55-siApollon-2 at an MOI of 1. After 24 h, the cells were trypsinized, washed and subcutaneously implanted (5 Â 10 6 cells per animal) into the right flank of each mouse. The tumor diameter was measured and the volume (product of length Â width 2 Â 0.5) was calculated. For the treatment of pre-established tumors, 5 Â 10 6 HT-1080 cells in 100 ml PBS were subcutaneously injected into the right flank of each mouse. When tumors reached 100-150 mm 3 , mice were divided randomly into seven groups (seven mice per group). Adenoviruses (2 Â 10 9 PFU per mouse) were injected into tumors every other day for three times. After injecting adenoviruses, mice were subsequently injected with 5-FU (Sigma, 30 mg kg
À1
, intraperitoneal) everyday for 5 days. The volume of tumors was recorded as mentioned above.
Immunohistochemistry
Immunohistochemistry was performed as described previously. 38 Tumor sections were incubated overnight with a mouse anti-Apollon antibody (BD Biosciences), followed by the biotinylated rat anti-mouse second antibody. The bound antibody complex was incubated with ABC-peroxidase regent (Bio-Genex laboratories, San Ramen, CA, USA) and diaminobenzidine substrate to develop the colorimetric reaction. Hematoxylin was used as a counterstain.
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay and quantification of apoptosis Apoptosis inside of tumors was assessed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling staining (In Situ Cell Apoptosis Detection Kit, Sino-American Biotechnology Company, Luoyang, China) according to the manufacturer's protocol as described previously. 39 Apoptotic cells were counted under a light microscope ( Â 400 magnification) in five randomly chosen fields and the apoptotic index was calculated as a percentage of all cancer cells in these fields.
Statistical analysis
Data were expressed as the means±s.d. and were analyzed using independent samples t-test and oneway analysis of variance as appropriate by a statistical software (SPSS Base 10.0 for Windows, SPSS Inc., Chicago, IL, USA). Results were considered statistically significant at Po0.05.
